Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib.

Kok CH, Yeung DT, Lu L, Watkins DB, Leclercq TM, Dang P, Saunders VA, Reynolds J, White DL, Hughes TP.

Blood Adv. 2019 May 28;3(10):1610-1621. doi: 10.1182/bloodadvances.2019000195.

2.

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines.

Lu L, Kok CH, Saunders VA, Wang J, McLean JA, Hughes TP, White DL.

Oncotarget. 2018 Oct 5;9(78):34735-34747. doi: 10.18632/oncotarget.26187. eCollection 2018 Oct 5.

3.

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.

Ross DM, Pagani IS, Shanmuganathan N, Kok CH, Seymour JF, Mills AK, Filshie RJ, Arthur CK, Dang P, Saunders VA, Braley J, Yong AS, Yeung DT, White DL, Grigg AP, Schwarer AP, Branford S, Hughes TP; Australasian Leukaemia and Lymphoma Group (ALLG).

Leukemia. 2018 Dec;32(12):2572-2579. doi: 10.1038/s41375-018-0264-0. Epub 2018 Oct 12.

PMID:
30315232
4.

Co-fuse: a new class discovery analysis tool to identify and prioritize recurrent fusion genes from RNA-sequencing data.

Paisitkriangkrai S, Quek K, Nievergall E, Jabbour A, Zannettino A, Kok CH.

Mol Genet Genomics. 2018 Oct;293(5):1217-1229. doi: 10.1007/s00438-018-1454-1. Epub 2018 Jun 7.

PMID:
29882166
5.

Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression.

McClure BJ, Heatley SL, Kok CH, Sadras T, An J, Hughes TP, Lock RB, Yeung D, Sutton R, White DL.

Br J Cancer. 2018 Apr;118(7):1000-1004. doi: 10.1038/s41416-018-0022-0. Epub 2018 Mar 13.

6.

A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH.

Sadras T, Heatley SL, Kok CH, McClure BJ, Yeung D, Hughes TP, Sutton R, Ziegler DS, White DL.

Cancer Genet. 2017 Oct;216-217:86-90. doi: 10.1016/j.cancergen.2017.07.008. Epub 2017 Jul 31.

PMID:
29025600
7.

High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment.

Heatley SL, Sadras T, Kok CH, Nievergall E, Quek K, Dang P, McClure B, Venn N, Moore S, Suttle J, Law T, Ng A, Muskovic W, Norris MD, Revesz T, Osborn M, Moore AS, Suppiah R, Fraser C, Alvaro F, Hughes TP, Mullighan CG, Marshall GM, Pozza LD, Yeung DT, Sutton R, White DL.

Haematologica. 2017 Dec;102(12):e490-e493. doi: 10.3324/haematol.2016.162925. Epub 2017 Sep 21. No abstract available.

8.

Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.

Sadras T, Heatley SL, Kok CH, Dang P, Galbraith KM, McClure BJ, Muskovic W, Venn NC, Moore S, Osborn M, Revesz T, Moore AS, Hughes TP, Yeung D, Sutton R, White DL.

Cancer Lett. 2017 Nov 1;408:92-101. doi: 10.1016/j.canlet.2017.08.034. Epub 2017 Sep 1.

PMID:
28866095
9.

A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia.

Pagani IS, Kok CH, Saunders VA, Van der Hoek MB, Heatley SL, Schwarer AP, Hahn CN, Hughes TP, White DL, Ross DM.

J Mol Diagn. 2017 Sep;19(5):711-721. doi: 10.1016/j.jmoldx.2017.05.009. Epub 2017 Jul 18.

PMID:
28732215
10.

A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm.

Casolari DA, Nguyen T, Butcher CM, Iarossi DG, Hahn CN, Bray SC, Neufing P, Parker WT, Feng J, Maung KZY, Wee A, Vidovic L, Kok CH, Bardy PG, Branford S, Lewis ID, Lane SW, Scott HS, Ross DM, D'Andrea RJ.

Sci Rep. 2017 May 26;7(1):2467. doi: 10.1038/s41598-017-02655-7.

11.

miR-155 as a potential target of IL-3 signaling in primary AML cells.

Sadras T, Kok CH, Perugini M, Ramshaw HS, D'Andrea RJ.

Leuk Res. 2017 Jun;57:57-59. doi: 10.1016/j.leukres.2017.02.010. Epub 2017 Mar 4.

PMID:
28301819
12.

Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells.

Wang J, Lu L, Kok CH, Saunders VA, Goyne JM, Dang P, Leclercq TM, Hughes TP, White DL.

Haematologica. 2017 May;102(5):843-853. doi: 10.3324/haematol.2016.153270. Epub 2017 Feb 2.

13.

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.

Nievergall E, Reynolds J, Kok CH, Watkins DB, Biondo M, Busfield SJ, Vairo G, Fuller K, Erber WN, Sadras T, Grose R, Yeung DT, Lopez AF, Hiwase DK, Hughes TP, White DL.

Leukemia. 2016 Jun;30(6):1263-72. doi: 10.1038/leu.2016.34. Epub 2016 Feb 22.

PMID:
26898188
14.

Levels of innate immune factors in preterm and term mothers' breast milk during the 1st month postpartum.

Trend S, Strunk T, Lloyd ML, Kok CH, Metcalfe J, Geddes DT, Lai CT, Richmond P, Doherty DA, Simmer K, Currie A.

Br J Nutr. 2016 Apr 14;115(7):1178-93. doi: 10.1017/S0007114516000234. Epub 2016 Feb 19.

PMID:
26891901
15.

PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.

Noll JE, Vandyke K, Hewett DR, Mrozik KM, Bala RJ, Williams SA, Kok CH, Zannettino AC.

J Hematol Oncol. 2015 Oct 6;8:106. doi: 10.1186/s13045-015-0209-2.

16.

Leukocyte Populations in Human Preterm and Term Breast Milk Identified by Multicolour Flow Cytometry.

Trend S, de Jong E, Lloyd ML, Kok CH, Richmond P, Doherty DA, Simmer K, Kakulas F, Strunk T, Currie A.

PLoS One. 2015 Aug 19;10(8):e0135580. doi: 10.1371/journal.pone.0135580. eCollection 2015.

17.

Antimicrobial protein and Peptide concentrations and activity in human breast milk consumed by preterm infants at risk of late-onset neonatal sepsis.

Trend S, Strunk T, Hibbert J, Kok CH, Zhang G, Doherty DA, Richmond P, Burgner D, Simmer K, Davidson DJ, Currie AJ.

PLoS One. 2015 Feb 2;10(2):e0117038. doi: 10.1371/journal.pone.0117038. eCollection 2015.

18.

Interleukin-3-mediated regulation of β-catenin in myeloid transformation and acute myeloid leukemia.

Sadras T, Perugini M, Kok CH, Iarossi DG, Heatley SL, Brumatti G, Samuel MS, To LB, Lewis ID, Lopez AF, Ekert PG, Ramshaw HS, D'Andrea RJ.

J Leukoc Biol. 2014 Jul;96(1):83-91. doi: 10.1189/jlb.2AB1013-559R. Epub 2014 Mar 5.

PMID:
24598054
19.

Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients.

Kok CH, Leclercq T, Watkins DB, Saunders V, Wang J, Hughes TP, White DL.

Leukemia. 2014 Mar;28(3):702-5. doi: 10.1038/leu.2013.329. Epub 2013 Nov 6. No abstract available.

PMID:
24192813
20.

HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia.

Brumatti G, Salmanidis M, Kok CH, Bilardi RA, Sandow JJ, Silke N, Mason K, Visser J, Jabbour AM, Glaser SP, Okamoto T, Bouillet P, D'Andrea RJ, Ekert PG.

Oncotarget. 2013 Nov;4(11):1933-47.

21.

Phagocytosis of neonatal pathogens by peripheral blood neutrophils and monocytes from newborn preterm and term infants.

Prosser A, Hibbert J, Strunk T, Kok CH, Simmer K, Richmond P, Burgner D, Currie A.

Pediatr Res. 2013 Nov;74(5):503-10. doi: 10.1038/pr.2013.145. Epub 2013 Sep 2.

PMID:
23999070
22.

Methylation of KLF5 contributes to reduced expression in acute myeloid leukaemia and is associated with poor overall survival.

Diakiw SM, Perugini M, Kok CH, Engler GA, Cummings N, To LB, Wei AH, Lewis ID, Brown AL, D'Andrea RJ.

Br J Haematol. 2013 Jun;161(6):884-8. doi: 10.1111/bjh.12295. Epub 2013 Mar 25. No abstract available.

PMID:
23521344
23.

Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation.

Kok CH, Watkins DB, Leclercq T, D'Andrea RJ, Hughes TP, White DL.

Leukemia. 2013 Jun;27(6):1427-30. doi: 10.1038/leu.2013.47. Epub 2013 Feb 15. No abstract available.

PMID:
23411466
24.

The preferential occurrence of FLT3-TKD mutations in inv(16) AML and impact on survival outcome: a combined analysis of 1053 core-binding factor AML patients.

Kok CH, Brown AL, Perugini M, Iarossi DG, Lewis ID, D'Andrea RJ.

Br J Haematol. 2013 Feb;160(4):557-9. doi: 10.1111/bjh.12131. Epub 2012 Nov 28. No abstract available.

PMID:
23190472
25.

GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations.

Perugini M, Iarossi DG, Kok CH, Cummings N, Diakiw SM, Brown AL, Danner S, Bardy P, Bik To L, Wei AH, Lewis ID, D'Andrea RJ.

Leukemia. 2013 Jul;27(7):1588-92. doi: 10.1038/leu.2012.346. Epub 2012 Nov 28. No abstract available.

PMID:
23187294
26.

Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells.

Wang J, Hughes TP, Kok CH, Saunders VA, Frede A, Groot-Obbink K, Osborn M, Somogyi AA, D'Andrea RJ, White DL.

Br J Cancer. 2012 May 22;106(11):1772-8. doi: 10.1038/bjc.2012.173. Epub 2012 Apr 24.

27.

Genome-wide gene expression profiling identifies overlap with malignant adrenocortical tumours and novel mechanisms of inefficient steroidogenesis in familial ACTH-independent macronodular adrenal hyperplasia.

Gagliardi L, Ling KH, Kok CH, Carolan J, Brautigan P, Kenyon R, D'Andrea RJ, Van der Hoek M, Hahn CN, Torpy DJ, Scott HS.

Endocr Relat Cancer. 2012 May 24;19(3):L19-23. doi: 10.1530/ERC-11-0210. Print 2012 Jun. No abstract available.

PMID:
22383426
28.

p53-Dependent transcriptional responses to interleukin-3 signaling.

Jabbour AM, Gordon L, Daunt CP, Green BD, Kok CH, D'Andrea R, Ekert PG.

PLoS One. 2012;7(2):e31428. doi: 10.1371/journal.pone.0031428. Epub 2012 Feb 14.

29.

Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors.

Bard-Chapeau EA, Jeyakani J, Kok CH, Muller J, Chua BQ, Gunaratne J, Batagov A, Jenjaroenpun P, Kuznetsov VA, Wei CL, D'Andrea RJ, Bourque G, Jenkins NA, Copeland NG.

Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2168-73. doi: 10.1073/pnas.1119229109. Epub 2012 Jan 19.

30.

The GM-CSF receptor utilizes β-catenin and Tcf4 to specify macrophage lineage differentiation.

Brown AL, Salerno DG, Sadras T, Engler GA, Kok CH, Wilkinson CR, Samaraweera SE, Sadlon TJ, Perugini M, Lewis ID, Gonda TJ, D'Andrea RJ.

Differentiation. 2012 Jan;83(1):47-59. doi: 10.1016/j.diff.2011.08.003. Epub 2011 Oct 8.

31.

The granulocyte-associated transcription factor Krüppel-like factor 5 is silenced by hypermethylation in acute myeloid leukemia.

Diakiw SM, Kok CH, To LB, Lewis ID, Brown AL, D'Andrea RJ.

Leuk Res. 2012 Jan;36(1):110-6. doi: 10.1016/j.leukres.2011.09.013. Epub 2011 Oct 11.

PMID:
21993314
32.

Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.

Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, Li XC, Babic M, Lin M, Carmagnac A, Lee YK, Kok CH, Gagliardi L, Friend KL, Ekert PG, Butcher CM, Brown AL, Lewis ID, To LB, Timms AE, Storek J, Moore S, Altree M, Escher R, Bardy PG, Suthers GK, D'Andrea RJ, Horwitz MS, Scott HS.

Nat Genet. 2011 Sep 4;43(10):1012-7. doi: 10.1038/ng.913.

33.

Gene expression analysis reveals HOX gene upregulation in trisomy 8 AML.

Kok CH, Brown AL, Ekert PG, D'Andrea RJ.

Leukemia. 2010 Jun;24(6):1239-43. doi: 10.1038/leu.2010.85. Epub 2010 Apr 29. No abstract available.

PMID:
20428200
34.

Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML.

Powell JA, Thomas D, Barry EF, Kok CH, McClure BJ, Tsykin A, To LB, Brown A, Lewis ID, Herbert K, Goodall GJ, Speed TP, Asou N, Jacob B, Osato M, Haylock DN, Nilsson SK, D'Andrea RJ, Lopez AF, Guthridge MA.

Blood. 2009 Nov 26;114(23):4859-70. doi: 10.1182/blood-2009-02-204818. Epub 2009 Oct 5.

PMID:
19805619
35.

Placental transfer of SSRI and SNRI antidepressants and effects on the neonate.

Rampono J, Simmer K, Ilett KF, Hackett LP, Doherty DA, Elliot R, Kok CH, Coenen A, Forman T.

Pharmacopsychiatry. 2009 May;42(3):95-100. doi: 10.1055/s-0028-1103296. Epub 2009 May 18.

PMID:
19452377
36.

Repression of Gadd45alpha by activated FLT3 and GM-CSF receptor mutants contributes to growth, survival and blocked differentiation.

Perugini M, Kok CH, Brown AL, Wilkinson CR, Salerno DG, Young SM, Diakiw SM, Lewis ID, Gonda TJ, D'Andrea RJ.

Leukemia. 2009 Apr;23(4):729-38. doi: 10.1038/leu.2008.349. Epub 2009 Jan 8.

PMID:
19151789
37.

Genetic regulators of myelopoiesis and leukemic signaling identified by gene profiling and linear modeling.

Brown AL, Wilkinson CR, Waterman SR, Kok CH, Salerno DG, Diakiw SM, Reynolds B, Scott HS, Tsykin A, Glonek GF, Goodall GJ, Solomon PJ, Gonda TJ, D'Andrea RJ.

J Leukoc Biol. 2006 Aug;80(2):433-47. Epub 2006 Jun 12.

PMID:
16769770
38.

Nonconjugative R plasmid-mediated antibiotic resistance in Escherichia coli isolated from animals in Peninsular Malaysia.

Koh CL, Kok CH.

Southeast Asian J Trop Med Public Health. 1984 Sep;15(3):313-6.

PMID:
6395350
39.

Supplemental Content

Support Center